Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 902-908

  Schneider, Paul M ^a,b   Metzger, Ralf ^a   Schaefer, Hartmut ^a   Baumgarten, Frank ^a   Vallbohmer, Daniel ^a   Brabender, Jan ^a   Wolfgarten, Eva ^a   Bollschweiler, Elfriede ^a   Baldus, Stephan E ^c   Dienes, Hans P ^a   Hoelscher, Arnulf H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR CELL; TUMOR REGRESSION; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; CANCER STAGING; ESOPHAGUS TUMOR; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 58149402944     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31818f3afb     Document Type: Article

References (37)

1. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151-159.
2. Lerut T, Coosemans W, Decker G, et al. Diagnosis and therapy in advanced cancer of the esophagus and the gastroesophageal junction. Curr Opin Gastroenterol. 2006;22:437-441.
3. Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729-746.
4. Sherman CA, Turrisi AT, Wallace MB, et al. Locally advanced esoph- ageal cancer. Curr Treat Options Oncol. 2002;3:475-485.
5. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240;962-972; discussion 972-974.
6. Altorki N. En-bloc esophagectomy-the three-field dissection. Surg Clin North Am. 2005;85:611-619.
7. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10: 754-761.
8. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002;185:538 -543.
9. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preopera- tive chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
10. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
11. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
12. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression afterpreoperative chemoradiotherapyofesophageal carcinoma. Clin- icopathologic correlations. Cancer. 1994;73:2680-2686.
13. Baldus SE, Monig SP, Schroder W, et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe. 2004;25:421-427.
14. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
15. Therasse P. Evaluation of response: new and standard criteria. Ann Oncol. 2002;13(suppl 4):127-129.
16. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011-1020.
17. Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91:199-204.
18. Sobin LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumours. 6th ed. NewYork, NY: Wiley-Liss; 2002.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:187-220.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
21. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am JSurgPathol. 2007;31:58-64.
22. Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int JRadiat Oncol Biol Phys. 2003;57:1328-1335.
23. Bedenne L, Seitz JF, Milan C, et al. Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. Gastroenterol Clin Biol. 1998;22:273-281.
24. Gill PG, Denham JW, Jamieson GG, et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. JClin Oncol. 1992;10:1037-1043.
25. Vogel SB, Mendenhall WM, Sombeck MD, et al. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg. 2995;221:685-693; discussion 693-695.
26. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. JClin Oncol. 1996;14:156-163.
27. Dittler HJ, Fink U, Siewert GR. Response to chemotherapy in esopha- geal cancer. Endoscopy. 1994;26:769-771.
28. Hordijk ML, Kok TC, Wilson JH, et al. Assessment of response of esophageal carcinoma to induction chemotherapy. Endoscopy. 1993;25: 592-596.
29. Tio LT, Blank LE, Wijers OB, et al. Staging and prognosis using endosonography in patients with inoperable esophageal carcinoma treated with combined intraluminal and external irradiation. Gastrointest Endosc. 1994;40:304-310.
30. Giovannini M, Bardou VJ, Moutardier V, et al. Relation between endoscopic ultrasound evaluation and survival of patients with inoperable thoracic squamous cell carcinoma of the oesophagus treated by combined radio- and chemotherapy. Ital JGastroenterol Hepatol. 1999; 31:593-597.
31. Zuccaro G Jr, Rice TW, Goldblum J, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol. 1999;94:906 -912.
32. Isenberg G, Chak A, Canto MI, et al. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc. 1998;48:158-163.
33. Willis J, Cooper GS, Isenberg G, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc. 2002;55:655-661.
34. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esoph- ageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
35. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368.
36. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160; discussion 1152-1160.
37. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophago- gastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8: 797-805.